AstraZeneca Stock (NASDAQ:AZN)
Previous Close
$64.44
52W Range
$60.47 - $87.68
50D Avg
$69.46
200D Avg
$74.95
Market Cap
$202.63B
Avg Vol (3M)
$5.57M
Beta
0.18
Div Yield
$1.48 (1.43%)
AZN Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Pulmicort | $713.00M | $645.00M | - |
| Roxadustat | $271.00M | $197.00M | $174.00M |
| Saphnelo | $280.00M | $116.00M | - |
| Seloken/Toprol-XL | $640.00M | $862.00M | - |
| Soliris | $3.15B | $3.76B | - |
| Strensiq | $1.15B | $958.00M | - |
| Andexxa | $182.00M | $150.00M | - |
| Zoladex | $952.00M | $927.00M | $948.00M |
| Vaxzevria | $12.00M | $1.80B | - |
| Ultomiris. | $2.96B | $1.97B | - |
| Total Other medicines | $1.18B | $1.63B | - |
| Total Oncology | $17.14B | $14.63B | - |
| Tagrisso | $5.80B | $5.44B | - |
| Synagis | $546.00M | $578.00M | - |
| Symbicort | $2.36B | $2.54B | - |
| Enhertu | $1.02B | $79.00M | $17.00M |
| Bevespi | $58.00M | $58.00M | - |
| Breztri | $677.00M | $398.00M | - |
| Brilinta | $1.32B | $1.36B | - |
| Bydureon | $163.00M | $280.00M | - |
| CVRM | $10.59B | $9.19B | - |
| Calquence | $2.51B | $2.06B | - |
| Crestor | $1.11B | $1.05B | $1.10B |
| Daliresp/Daxas | $54.00M | $189.00M | - |
| Farxiga | $5.96B | $4.38B | - |
| Fasenra | $1.55B | $1.40B | - |
| Faslodex | $297.00M | $334.00M | - |
| FluMist | $216.00M | $175.00M | - |
| Imfinzi | $4.24B | $2.78B | - |
| Kanuma | $171.00M | $160.00M | - |
| Koselugo | $331.00M | $208.00M | - |
| Lokelma | $412.00M | $289.00M | - |
| Lynparza | $2.81B | $2.64B | - |
| Nexium | $945.00M | $1.28B | $1.33B |
| Oncology, Others | $224.00M | $44.00M | - |
| Onglyza | $227.00M | $257.00M | - |
| Other, Others | $231.00M | $340.00M | - |
| Rare Disease | $7.76B | $7.05B | - |
| Ophatys | - | $33.00M | - |
| Iressa | - | $114.00M | - |
| Casodex | - | $78.00M | - |
| BioPharmaceuticals: total Respiratory & Immunology | - | $5.76B | - |
| Arimidex | - | $99.00M | - |
| Respiratory, Others | - | $421.00M | - |
| Other Ongoing Collaboration Revenue | - | - | $64.00M |
| Lynparza/Koselugo | - | - | $400.00M |
| Royal income | - | - | $138.00M |
| Profit share revenue from product sales by collaboration partners | - | - | $200.00M |
| Collaboration Revenue | - | - | $12.00M |
Fiscal year ends in Dec 23 | Currency in USD